Morgan Stanley Upgrades Boston Scientific on Pipeline Acceleration

In a report published Monday, Morgan Stanley analyst David Lewis upgraded Boston Scientific (NYSE: BSX ) from Equal-weight to Overweight based on pipeline acceleration traction. Despite disappointing pipeline progress in 2013 from Asthmatx reimbursement delays and S-ICD manufacturing constraints, Morgan Stanley expects sales results to improve. Morgan Stanley's updated model